Evidence map›Paper›PMID 39285246›Full record

ArticleEMBO reports2024

SOX10 mediates glioblastoma cell-state plasticity.

Ka-Hou Man, Yonghe Wu, Zhenjiang Gao, Anna-Sophie Spreng, Johanna Keding, Jasmin Mangei, Pavle Boskovic, Jan-Philipp Mallm, Hai-Kun Liu, Charles D Imbusch and 2 more

Abstract read
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. [Journal of neuro-oncology · 2026
    Article
  5. Article
  6. Article
  7. European journal of breast health · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ka-Hou Man *Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8388-1541
Yonghe Wu *Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.ORCID 0000-0001-9667-8198
Zhenjiang GaoShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Anna-Sophie SprengDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Johanna KedingDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jasmin MangeiDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pavle BoskovicDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-2185-7121
Jan-Philipp MallmSingle-Cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7059-4030
Hai-Kun LiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Charles D ImbuschDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4920-551X
Peter LichterDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-2960-5279
Bernhard RadlwimmerDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. b.radlwimmer@dkfz.de.ORCID 0000-0002-4553-7800

Funding

DKFZ | Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft (DKFZ-HIPO) HIPO016
6 · The paper itself

Abstract

Phenotypic plasticity is a cause of glioblastoma therapy failure. We previously showed that suppressing the oligodendrocyte-lineage regulator SOX10 promotes glioblastoma progression. Here, we analyze SOX10-mediated phenotypic plasticity and exploit it for glioblastoma therapy design. We show that low SOX10 expression is linked to neural stem-cell (NSC)-like glioblastoma cell states and is a consequence of temozolomide treatment in animal and cell line models. Single-cell transcriptome profiling of Sox10-KD tumors indicates that Sox10 suppression is sufficient to induce tumor progression to an aggressive NSC/developmental-like phenotype, including a quiescent NSC-like cell population. The quiescent NSC state is induced by temozolomide and Sox10-KD and reduced by Notch pathway inhibition in cell line models. Combination treatment using Notch and HDAC/PI3K inhibitors extends the survival of mice carrying Sox10-KD tumors, validating our experimental therapy approach. In summary, SOX10 suppression mediates glioblastoma progression through NSC/developmental cell-state transition, including the induction of a targetable quiescent NSC state. This work provides a rationale for the design of tumor therapies based on single-cell phenotypic plasticity analysis.

Indexed as

GlioblastomaSOXE Transcription FactorsTemozolomideAnimalsBrain NeoplasmsCell Line, TumorCell PlasticityGene Expression Regulation, NeoplasticHumansMiceNeural Stem CellsReceptors, NotchSignal TransductionSingle-Cell AnalysisReceptors, NotchSOX10 protein, humanSOXE Transcription FactorsTemozolomideGlioblastomaPhenotypic PlasticitySOX10Therapy ResistanceTumor Cell Quiescence

Identifiers

PMID39285246
PMCPMC11549307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.